Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 6/20 | 0.76 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19500443 | 0.89 | IGF2R (0.78) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL19509824 | 0.89 | IGF2R (0.78) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL19509827 | 0.89 | IGF2R (0.78) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL21470012 | 0.89 | IGF2R (0.78) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL933188 | 0.87 | IGF2R (0.75) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL2615799 | 0.87 | IGF2R (0.75) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL1871036 | 0.85 | IGF2R (0.85) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL7995162 | 0.85 | IGF2R (0.85) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL7993492 | 0.84 | IGF2R (0.80) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL14275246 | 0.83 | IGF2R (0.64) | IGF2RFBP1AMDHD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649459-B2 | Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11034958-B2 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210108203-A1 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2021-04-15 | — | — | US | disclosed |
| US-20200385719-A1 | KISSPEPTIN 1 (KISS1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200208150-A1 | METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) | ALNYLAM PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10550390-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190352645-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2019-11-21 | — | — | US | disclosed |
| US-20190316137-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2019-10-17 | — | — | US | disclosed |
| US-10231988-B2 | Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180066255-A1 | Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes | BANK OF AMERICA, N.A. | 2018-03-08 | — | — | US | disclosed |
| US-20170340661-A1 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550390-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | TEK, RNASE1, LDLR | IGF2R 307/4885FBP1 398/4885AMDHD2 1193/4885 |
| US-20170340661-A1 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PNPLA2, PLAAT3, PNLIP | IGF2R 787/4885FBP1 1279/4885AMDHD2 682/4885 |
| US-20190316137-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TEK, RNASE1, LDLR | IGF2R 307/4885FBP1 398/4885AMDHD2 1193/4885 |
| US-10231988-B2 | Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof | PNPLA2, PLAAT3, PNLIP | IGF2R 787/4885FBP1 1279/4885AMDHD2 682/4885 |
| US-20200208150-A1 | METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) | TFPI, F12, TFPI2 | IGF2R 927/4885FBP1 2326/4885AMDHD2 2788/4885 |
| US-20190352645-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TEK, RNASE1, LDLR | IGF2R 307/4885FBP1 398/4885AMDHD2 1193/4885 |
| US-11649459-B2 | Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases | SOD1, SOD3, SMN1; SMN2 | IGF2R 1814/4885FBP1 1398/4885AMDHD2 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.